A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression
Prostate Cancer
DRUG: CC5013
To determine the activity of lenalidomide monotherapy in subjects with androgen independent prostate cancer (AIPC).
To evaluate the safety of lenalidomide monotherapy as treatment for subjects with AIPC.
Subjects who qualify will receive single agent oral lenalidomide daily on days 1-21 every 28 day cycle. Subjects will continue on study until documented disease progression